Date: 2015-05-11
Type of information: IPO
Company: Adaptimmune (UK)
Investors:
Amount: $175.7 million
Funding type: IPO
Planned used:
Others: * On May 11, 2015, Adaptimmune announced the closing of its initial public offering of 11,250,000 American Depositary Shares (ADSs) at a price to the public of $17.00 per ADS. The aggregate net proceeds to Adaptimmune, after underwriting discounts and commissions and estimated offering expenses, were approximately $175.7 million. As previously reported, Adaptimmune has granted the underwriters a 30-day option to purchase up to an additional 1,687,500 ADSs. A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission (SEC) on May 5, 2015. * On May 6, 2015, Adaptimmune Therapeutics announced the pricing of its initial public offering of 11,250,000 American Depositary Shares (ADSs) at a price to the public of $17.00 per ADS. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,687,500 ADSs. The ADSs are expected to begin trading on the NASDAQ Global Select Market under the symbol “ADAP” on May 6, 2015. The offering is expected to close on May 11, 2015, subject to customary closing conditions. Adaptimmune estimates net proceeds from the offering will be approximately $175.7 million. BofA Merrill Lynch, Cowen and Company and Leerink Partners LLC are acting as joint book-running managers and Guggenheim Securities is acting as lead manager for the offering. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (SEC) on May 5, 2015. This offering is made only by means of a written prospectus forming part of the effective registration statement.
Therapeutic area: Cancer - Oncology
